QULIPTA™ Long-Term Safety Study Results

Safety observed
in a
long-term,
52-week safety study

ADVERSE EVENT ≥5%3* QULIPTA 60 mg QD (n=543)
Upper respiratory tract infection 10%
Constipation 7%
Nausea 6%
Urinary tract infection 5%

*The majority of the cases were mild, and none were serious.

31/543 patients (5.7%) discontinued due to adverse events.3

Open-label, Long-term Safety Study

A multicenter, randomized, open-label, 52-week long-term safety study to evaluate the safety and tolerability of QULIPTA 60 mg in participants who experienced 4 to 14 migraine days per month. Participants were randomized to either QULIPTA 60 mg once-daily or oral standard-of-care migraine prevention medication. Efficacy measures were only collected for the QULIPTA group. For the 521 participants in the QULIPTA group in the mITT population, mean age was 42.5 years (range 18 to 78 years), 88.3% were female, 76.8% were White, 15.7% were of Hispanic or Latino ethnicity.3

see efficacy data